SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis
USA - NASDAQ:SUPN - US8684591089 - Common Stock
45 USD
+0.56 (+1.26%)
45 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to SUPN. SUPN was compared to 191 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making SUPN a very profitable company, without any liquidiy or solvency issues. SUPN is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, SUPN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
In the past year SUPN had a positive cash flow from operations.
In the past 5 years SUPN has always been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.67%, SUPN belongs to the top of the industry, outperforming 86.39% of the companies in the same industry.
SUPN's Return On Equity of 6.06% is amongst the best of the industry. SUPN outperforms 85.34% of its industry peers.
The Return On Invested Capital of SUPN (4.10%) is better than 82.72% of its industry peers.
SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 15.35%.
The last Return On Invested Capital (4.10%) for SUPN is above the 3 year average (2.70%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.67% | ||
| ROE | 6.06% | ||
| ROIC | 4.1% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
Looking at the Profit Margin, with a value of 9.70%, SUPN belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
In the last couple of years the Profit Margin of SUPN has declined.
SUPN has a Operating Margin of 10.98%. This is amongst the best in the industry. SUPN outperforms 84.29% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
Looking at the Gross Margin, with a value of 89.87%, SUPN belongs to the top of the industry, outperforming 92.67% of the companies in the same industry.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.98% | ||
| PM (TTM) | 9.7% | ||
| GM | 89.87% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
Compared to 1 year ago, SUPN has more shares outstanding
The number of shares outstanding for SUPN has been increased compared to 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 6.88 indicates that SUPN is not in any danger for bankruptcy at the moment.
The Altman-Z score of SUPN (6.88) is better than 81.68% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.88 |
ROIC/WACC0.46
WACC8.88%
2.3 Liquidity
SUPN has a Current Ratio of 2.58. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
SUPN has a Current ratio (2.58) which is in line with its industry peers.
SUPN has a Quick Ratio of 2.43. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
SUPN has a Quick ratio (2.43) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.32% over the past year.
Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.93% on average per year.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 4.54%.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
The Earnings Per Share is expected to grow by 19.13% on average over the next years. This is quite good.
Based on estimates for the next years, SUPN will show a quite strong growth in Revenue. The Revenue will grow by 14.60% on average per year.
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.13%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.6%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 14.52, SUPN is valued correctly.
SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 86.91% of the companies in the same industry.
When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (25.89), we can say SUPN is valued slightly cheaper.
With a Price/Forward Earnings ratio of 14.52, SUPN is valued correctly.
Based on the Price/Forward Earnings ratio, SUPN is valued cheaper than 82.72% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.59. SUPN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.52 | ||
| Fwd PE | 14.52 |
4.2 Price Multiples
83.77% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
SUPN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SUPN is cheaper than 86.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.2 | ||
| EV/EBITDA | 12.29 |
4.3 Compensation for Growth
SUPN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.09
EPS Next 2Y2.48%
EPS Next 3Y10.42%
5. Dividend
5.1 Amount
No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45
+0.56 (+1.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners109.54%
Inst Owner Change-2.2%
Ins Owners4.2%
Ins Owner Change2.53%
Market Cap2.83B
Revenue(TTM)681.54M
Net Income(TTM)64.50M
Analysts83.33
Price Target59.36 (31.91%)
Short Float %8.21%
Short Ratio7.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.64%
Min EPS beat(2)15.55%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)84.8%
Min EPS beat(4)15.55%
Max EPS beat(4)158.74%
EPS beat(8)7
Avg EPS beat(8)81.53%
EPS beat(12)8
Avg EPS beat(12)38.3%
EPS beat(16)10
Avg EPS beat(16)29.24%
Revenue beat(2)1
Avg Revenue beat(2)2.29%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)6.02%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.08%
Revenue beat(12)8
Avg Revenue beat(12)2.78%
Revenue beat(16)11
Avg Revenue beat(16)2.43%
PT rev (1m)32.88%
PT rev (3m)44.78%
EPS NQ rev (1m)105.81%
EPS NQ rev (3m)86.31%
EPS NY rev (1m)19.04%
EPS NY rev (3m)55.99%
Revenue NQ rev (1m)1.77%
Revenue NQ rev (3m)12.67%
Revenue NY rev (1m)1.47%
Revenue NY rev (3m)9.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.52 | ||
| Fwd PE | 14.52 | ||
| P/S | 4.25 | ||
| P/FCF | 15.2 | ||
| P/OCF | 15.1 | ||
| P/B | 2.66 | ||
| P/tB | 6.07 | ||
| EV/EBITDA | 12.29 |
EPS(TTM)3.1
EY6.89%
EPS(NY)3.1
Fwd EY6.89%
FCF(TTM)2.96
FCFY6.58%
OCF(TTM)2.98
OCFY6.62%
SpS10.59
BVpS16.95
TBVpS7.42
PEG (NY)N/A
PEG (5Y)2.09
Graham Number34.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.67% | ||
| ROE | 6.06% | ||
| ROCE | 6.66% | ||
| ROIC | 4.1% | ||
| ROICexc | 7.83% | ||
| ROICexgc | N/A | ||
| OM | 10.98% | ||
| PM (TTM) | 9.7% | ||
| GM | 89.87% | ||
| FCFM | 27.94% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.48% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.69% | ||
| Profit Quality | 288.18% | ||
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z | 6.88 |
F-Score8
WACC8.88%
ROIC/WACC0.46
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.13%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.6%
EBIT growth 1Y56.36%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year-16.93%
EBIT Next 3Y25.95%
EBIT Next 5Y31.31%
FCF growth 1Y161.05%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y160.89%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 7 / 10 to SUPN.
Can you provide the valuation status for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 7 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Undervalued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 8 / 10.
What is the valuation of SUPERNUS PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.52 and the Price/Book (PB) ratio is 2.66.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 7 / 10.